Keywords: sweden, tlv, rejects, 1st-line, use, pfizer, lipitor

Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential

Article | 23 February 2009

Print This

Sweden's Dental and Pharmaceutical Benefits Agency, the TLV, has presented its review of lipid-lowering drugs, effective June 1, in a ruling ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in